EDAP
NASDAQEDAP TMS S.A.
News · 26 weeks47-76%
2025-12-142026-06-07
Mix3290d
- SEC Filings16(50%)
- Insider6(19%)
- Other5(16%)
- Earnings3(9%)
- Leadership2(6%)
Latest news
25 items- SECEDAP TMS S.A. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - EDAP TMS SA (0001041934) (Filer)
- SECEDAP TMS S.A. filed SEC Form 8-K: Other Events8-K - EDAP TMS SA (0001041934) (Filer)
- PREDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol "FOCL" at Market Open on June 1, 2026Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments as Discontinued Operations Beginning with Second Quarter 2026 Financial ResultsInvestor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity AUSTIN, Texas, May 29, 2026 - EDAP TMS S.A. (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announce
- PREDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4th, 2026 AUSTIN, Texas, May 21th, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Jefferies 2026 Global Healthcare Conference in New York. Date: Thursday, June 4th Time: 2:00-2:30 PM ET Format: Presentation and 1x1 investor meetings Webcast: https://event.summitcast.com
- PRTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesTelix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes. MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ:EDAP, "EDAP")) and Profound Medical Corp. (NASDAQ:PROF, TSX:PRN, "Profound")
- SECSEC Form DEFA14A filed by EDAP TMS S.A.DEFA14A - EDAP TMS SA (0001041934) (Filer)
- SECSEC Form DEFA14A filed by EDAP TMS S.A.DEFA14A - EDAP TMS SA (0001041934) (Filer)
- SECSEC Form DEF 14A filed by EDAP TMS S.A.DEF 14A - EDAP TMS SA (0001041934) (Filer)
- PREDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (NASDAQ:EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited ("Telix") to explore joint clinical research activities and physician education focused on the combination of EDAP's Focal One Robotic HIFU and Telix's PSMA PET imaging products in the management of prostate cancer. The initial area of investigational focus is expected to study the combination of PSMA PET diagnostic imaging scans within the Focal One HIFU treatment workflow to optimize treatment planning, deliver a precise, image-guided focal therapy treatment, and monitor responses after treatment and
- PREDAP | Focal One to Host Investor Day on June 1, 2026, May 13, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Host Investor Day on June 1, 2026 AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and investors at 8:00 am ET on Monday, June 1, 2026. The presentation will be led by members of the Company's Executive Leadership Team and will include remarks from a prominent urologic surgeon and expert in focal therapy and Focal One HIFU. The event will also cover an overview of the Company's business plans and strategic path forward, including our: Growth Strategy and Long-Term Financial TargetsExpanding Th
- INSIDERSVP, Marketing & Product Mgmt. Annen Steven was granted 90,000 shares, increasing direct ownership by 217% to 131,490 units (SEC Form 4)4 - EDAP TMS SA (0001041934) (Issuer)
- INSIDERDirector Levine Joshua bought $42,200 worth of shares (10,000 units at $4.22), increasing direct ownership by 40% to 35,000 units (SEC Form 4)4 - EDAP TMS SA (0001041934) (Issuer)
- INSIDERGen Counsel & Corp Secretary Shah Sanket was granted 67,500 shares (SEC Form 4)4 - EDAP TMS SA (0001041934) (Issuer)
- INSIDERSEC Form 4 filed by Director Willsey Lance4 - EDAP TMS SA (0001041934) (Issuer)
- INSIDERChief Executive Officer Rhodes Ryan was granted 304,500 shares, increasing direct ownership by 101% to 605,649 units (SEC Form 4)4 - EDAP TMS SA (0001041934) (Issuer)
- INSIDERChief Financial Officer Mobeck Kenneth S. was granted 120,000 shares, increasing direct ownership by 212% to 176,610 units (SEC Form 4)4 - EDAP TMS SA (0001041934) (Issuer)
- SECSEC Form 10-Q filed by EDAP TMS S.A.10-Q - EDAP TMS SA (0001041934) (Filer)
- SECEDAP TMS S.A. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - EDAP TMS SA (0001041934) (Filer)
- PREDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue, May 07, 2026 (GLOBE NEWSWIRE) -- EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue Seventh Consecutive Quarter of Year-Over-Year HIFU Revenue Growth 78% Growth in First Quarter HIFU Revenue Year-Over-Year53% Growth in First Quarter U.S. HIFU Procedures Year-Over-Year83% Growth in First Quarter Focal One Shipments Year-Over-Year Demonstrating Strong MomentumLandmark HIFI-2 Study Results Further Strengthen Focal One Robotic HIFU Market Position AUSTIN, Texas, May 7, 2026 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today reported financial results for the first quarter of 2026. "We delivered our strongest HIFU quarter t
- SECSEC Form PRE 14A filed by EDAP TMS S.A.PRE 14A - EDAP TMS SA (0001041934) (Filer)
- PREDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer, April 30, 2026 (GLOBE NEWSWIRE) -- EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer AUSTIN, Texas, April 30, 2026 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced the publication of the HIFI-2 study, a large, prospective, nationwide trial evaluating salvage high-intensity focused ultrasound (HIFU) using Focal One Robotic HIFU for the treatment of localized prostate cancer recurrence following radiotherapy. Published in European Urology Oncology, the study titled "Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy
- PREDAP to Announce First Quarter 2026 Financial Results on May 7, 2026, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT AUSTIN, Texas, April 16, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2026, before market open on Thursday, May 7, 2026. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for c
- SECEDAP TMS S.A. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - EDAP TMS SA (0001041934) (Filer)
- SECSEC Form EFFECT filed by EDAP TMS S.A.EFFECT - EDAP TMS SA (0001041934) (Filer)
- SECSEC Form 424B3 filed by EDAP TMS S.A.424B3 - EDAP TMS SA (0001041934) (Filer)
EDAP FAQ
7 questionsWhat does EDAP TMS S.A. do?
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three divisions: High Intensity Focused Ultrasound (HIFU); Extracorporeal ShockWave Lithotripsy (ESWL); and Distribution. The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an...Where does EDAP stock trade?
EDAP TMS S.A. (EDAP) is listed on NASDAQ.What sector and industry is EDAP in?
EDAP TMS S.A. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did EDAP TMS S.A. go public?
EDAP TMS S.A. (EDAP) completed its IPO in 1997.What are analysts saying about EDAP?
EDAP TMS S.A. has had 4 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral on 2025-05-15.What companies are similar to EDAP?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare EDAP side-by-side with any of them on Quantisnow.How can I track EDAP on Quantisnow?
Quantisnow aggregates EDAP TMS S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EDAP to receive live email and push alerts on every new disclosure.